Conn pharmaceutical executive to lead MassBiologics at UMass Medical School wbjournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wbjournal.com Daily Mail and Mail on Sunday newspapers.
Operator
Good morning, and welcome to the Bio-Techne Earnings Conference Call for the Third Quarter of Fiscal Year 2021. At this time, all participants have been placed in listen-only mode and the call will be open for questions following management s prepared remarks. During our Q&A session, please limit yourself to one question and a follow-up.
I would now like to turn the call over to David Clair, Bio-Techne s Senior Director, Investor Relations and Corporate Development.
David Clair
Senior Director-Investor Relations and Corporate Development
Good morning, and thank you for joining us. On the call with me this morning are Chuck Kummeth, Chief Executive Officer; and Jim Hippel, Chief Financial Officer of Bio-Techne.
Share this article
Share this article
MINNEAPOLIS, May 6, 2021 /PRNewswire/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ended March 31, 2021.
Third Quarter FY2021 Snapshot
Third quarter organic revenue increased by 22% (25% reported) to $243.6 million and 17% (19% reported) in the first nine months of fiscal 2021 to $672.0 million.
GAAP EPS was $1.12 versus $0.92 one year ago. Delivered adjusted earnings per share (EPS) of $1.79 versus $1.39 one year ago.
Adjusted Operating Margin increased to 40.1% in the third quarter of fiscal 2021 compared to 36.4% in the third quarter of fiscal 2020.
Excellent commercial execution in both operating segments with Protein Sciences achieving record organic growth of 24% and Diagnostics and Genomics delivering 17% organic growth.
Share this article
Share this article
MINNEAPOLIS and BOSTON, May 4, 2021 /PRNewswire/ Bio-Techne Corporation (NASDAQ: TECH) and 908 Devices (NASDAQ: MASS) today announced a joint collaboration to develop an extended workflow solution for protein characterization. Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, and owner of the leading ProteinSimple branded protein analysis portfolio of products, will pair its Maurice icIEF separation instrument with 908 Devices ZipChip device to deliver a seamless workflow for deeper protein characterization. Maurice and the iCE technology are the gold standard in protein characterization, providing absorbance and native fluorescence icIEF detection as well as CE-SDS, saving significant development time and reducing the time to commercialization.
Credit: Ulf Sirborn
The causes of the serious muscle disease ALS still remain unknown. Now, researchers at Karolinska Institutet and KTH Royal Institute of Technology, among others, have examined a type of cell in the brain blood vessels that could explain the unpredictable disease origins and dynamics. The results indicate a hitherto unknown connection between the nervous and vascular systems. The study, which is published in
Nature Medicine, has potential implications for earlier diagnoses and future treatments.
ALS (amyotrophic lateral sclerosis) is a neurodegenerative disease of the motor neurons that eventually causes muscular atrophy, paralysis and death. There is currently no cure.